RIKEN's New Research Center for Brain Science: RIKEN CBS Website


Faculty Detail / 研究室詳細

Kato Tadafumi, M.D., Ph.D.

- We will make efforts to develop new drugs for diseases of the CNS.

RIKEN BSI Takeda Collaboration Center (BTaC)

Director, BTaC

Central nervous system (CNS) diseases, New technology for drug design

Kato  Tadafumi

Research Area

Schizophrenia, amyotrophic lateral sclerosis (ALS), and bipolar disorders are central nervous system diseases for which no effective treatments currently exist. But tackling these diseases will require more than the usual drug discovery methodologies. If breakthroughs are to be achieved, it will be necessary to also apply a variety of elemental technology such as the analysis of gene expression within specific regions of the brain, bio-imaging, electrophysiology, and optogenetics.

Since its founding in 1997, RIKEN BSI has been carrying out basic research directed at developing elemental technologies in brain science and elucidating brain functions with a focus on neural circuits. The Takeda Pharmaceutical Company has built up a considerable database for drug discovery and its significant achievements in research and development related to the therapeutic areas such as metabolic and central nervous system diseases have made it one of the leading pharmaceutical companies in the world. The two organizations have come together to take advantage of RIKEN's program for RIKEN-industry collaboration centers to create a place in which there can be a streamlined process of research and development, starting with the elucidation of the central nervous system and the search for new drug targets and moving on to the invention of new drugs. The new Collaboration Center is expected to stimulate active exchange of personnel as scientists from RIKEN BSI and Takeda Pharmaceutical Company work closely together to forge new directions in research and achieve a far-reaching integration of knowledge, information and technology.